Jonsson Comprehensive Cancer Center
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.cancer.ucla.edu
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
Phase 2
Active, not recruiting
- Conditions
- Oligometastatic Prostate CarcinomaProstate AdenocarcinomaRecurrent Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
- Interventions
- Other: Quality-of-Life AssessmentRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 93
- Registration Number
- NCT05496959
- Locations
- πΊπΈ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant
Phase 1
Withdrawn
- Conditions
- Diffuse Hemispheric Glioma, H3 G34-Mutant
- Interventions
- Biological: Dendritic Cell Tumor Peptide VaccineProcedure: LeukapheresisDrug: Placebo AdministrationProcedure: Resection
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05457959
- Locations
- πΊπΈ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Phase 1
Recruiting
- Conditions
- Stage IVA Prostate Cancer AJCC v8Metastatic Prostate CarcinomaStage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05398302
- Locations
- πΊπΈ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Phase 1
Recruiting
- Conditions
- Metastatic HER2-Positive Breast CarcinomaPrognostic Stage IB Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8
- Interventions
- Other: Quality-of-Life Assessment
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT05319873
- Locations
- πΊπΈ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Phase 1
Recruiting
- Conditions
- Diffuse Large B-Cell LymphomaHigh-grade B-cell LymphomaTransformed LymphomaSecondary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05256641
- Locations
- πΊπΈ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈUniversity of California Davis Comprehensive Cancer Center, Sacramento, California, United States
πΊπΈUniversity of Oklahoma, Oklahoma City, Oklahoma, United States
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
Early Phase 1
Recruiting
- Conditions
- Prostate Carcinoma
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05160597
- Locations
- πΊπΈ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy
Not Applicable
Recruiting
- Conditions
- Locally Advanced Head and Neck Carcinoma
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05115760
- Locations
- πΊπΈ
University of California at Los Angeles, Los Angeles, California, United States
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
Early Phase 1
Recruiting
- Conditions
- Recurrent GliomaRecurrent Malignant GliomaGliomaMalignant Glioma
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05045027
- Locations
- πΊπΈ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
A Mobile Phone Intervention to Promote Adherence to Survivorship Care Among Adolescent and Young Adult Cancer Survivors
Early Phase 1
Withdrawn
- Conditions
- Survivors of Childhood Cancer
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT05000359
- Locations
- πΊπΈ
University of California at Los Angeles, Los Angeles, California, United States
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
Not Applicable
Recruiting
- Conditions
- Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8Stage IIIC Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT04945642
- Locations
- πΊπΈ
University of California at Los Angeles / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States